EXAGEN INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
EXAGEN INC. (XGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 433.70 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-04
- EXAGEN INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 243.70K shares, a 392.32% increase year-over-year.
- EXAGEN INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 190.00K shares, a 58.24% increase year-over-year.
- EXAGEN INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares.
- EXAGEN INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- EXAGEN INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 169.57K shares, a 205.53% increase from fiscal 2024.
- EXAGEN INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 55.50K shares, a 24.49% decline from fiscal 2023.
- EXAGEN INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 73.50K shares, a 16.67% increase from fiscal 2022.
- EXAGEN INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 63.00K shares, a 72.59% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 243.70K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 433.70K shares 10-Q · filed 2026-08-04 | 433.70K shares derived: sum of 3 quarters · filed 2026-08-04 | 433.70K shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | 190.00K shares 10-Q · filed 2026-05-11 | 190.00K shares derived: sum of 2 quarters · filed 2026-05-11 | 190.00K shares derived: sum of 3 quarters · filed 2026-05-11 | 239.50K shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-10 | 49.50K shares derived: sum of 3 quarters · filed 2026-08-04 | 169.57K shares 10-K · filed 2026-03-10 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 49.50K shares derived: sum of 2 quarters · filed 2026-08-04 | 169.57K shares 10-Q · filed 2025-11-04 | 169.57K shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | 49.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | 169.57K shares 10-Q · filed 2026-08-04 | 169.57K shares derived: sum of 3 quarters · filed 2026-08-04 | 169.57K shares derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | 120.07K shares 10-Q · filed 2026-05-11 | 120.07K shares derived: sum of 2 quarters · filed 2026-05-11 | 120.07K shares derived: sum of 3 quarters · filed 2026-05-11 | 175.57K shares derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | 0.00 shares derived: sum of 2 quarters · filed 2026-03-10 | 55.50K shares derived: sum of 3 quarters · filed 2026-03-10 | 55.50K shares 10-K · filed 2026-03-10 |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 55.50K shares derived: sum of 2 quarters · filed 2025-11-04 | 55.50K shares 10-Q · filed 2025-11-04 | |
| 2024-06-30 | 55.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-29 | 55.50K shares 10-Q · filed 2025-07-29 | ||
| 2024-03-31 | 0.00 shares 10-Q · filed 2025-05-05 | |||
| 2023-12-31 | 73.50K shares 10-K · filed 2024-03-18 | |||
| 2022-12-31 | 63.00K shares 10-K · filed 2023-03-20 | |||
| 2022-03-31 | 0.00 shares 10-Q · filed 2022-05-11 | |||
| 2021-12-31 | 229.85K shares 10-K · filed 2022-03-22 | |||
| 2020-12-31 | 49.50K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | 370.30K shares derived: sum of 2 quarters · filed 2021-03-16 | 436.90K shares derived: sum of 3 quarters · filed 2021-03-16 | 951.03K shares 10-K · filed 2021-03-16 |
| 2020-09-30 | 320.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-10 | 387.40K shares derived: sum of 2 quarters · filed 2020-11-10 | 901.53K shares 10-Q · filed 2020-11-10 | 903.55K shares derived: sum of 4 quarters · filed 2020-11-10 |
| 2020-06-30 | 66.60K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-28 | 580.73K shares 10-Q · filed 2020-07-28 | 582.75K shares derived: sum of 3 quarters · filed 2020-07-28 | |
| 2020-03-31 | 514.13K shares 10-Q · filed 2020-05-11 | 516.15K shares derived: sum of 2 quarters · filed 2020-05-11 | ||
| 2019-12-31 | 2.02K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | 816.36K shares 10-K · filed 2020-03-25 | ||
| 2019-09-30 | 814.34K shares 10-Q · filed 2019-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B | ||
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |